Jul 2026· Current Neurovascular Research· Vol 23· 0 citations
Medicine
TL;DR
DYRK1A exemplifies precision medicine for dosage-sensitive genes where therapeutic success depends on restoring physiological balance, and Species divergence between rodent and human iPSC models, combined with inter-individual variability, underscores the limitations of current mechanistic models.
Abstract
INTRODUCTION
DYRK1A (dual-specificity tyrosine phosphorylation-regulated kinase 1A) is a dosage-sensitive regulator of central nervous system development. Dysregulation contributes to major neurodevelopmental disorders, including Down Syndrome (DS), Autism Spectrum Disorder (ASD), and Intellectual Developmental Disorder (IDD). This review critically examines how DYRK1A dosage shapes neurodevelopment, neurotransmitter regulation, and disease phenotypes.
Methods
We synthesized molecular, cellular, and systems-level evidence (2015-2025) from rodent DYRK1A mutant models, human iPSC-derived neural progenitors, and human transcriptomic datasets using comprehensive searches of PubMed, Google Scholar, and Web of Science. Studies were assessed for mechanistic rigor, species applicability, and translational potential.
Results
Recent studies reveal that DYRK1A coordinates four neurodevelopmental processes: (1) neural progenitor proliferation/differentiation via cell cycle regulation (cyclin D1, p27Kip1, E2F2, NeuroD1); (2) chromatin remodeling through histone acetyltransferase phosphorylation (EP300, CREBBP); (3) glutamatergic synaptic transmission via presynaptic gene suppression (RIMS1, Munc13-1, Syn2), impairing NMDA-independent long-term potentiation; (4) glial differentiation and myelination. DYRK1A overexpression in DS disrupts neurogenesis and synaptic connectivity; haploinsufficiency causes microcephaly and intellectual disability. Species divergence between rodent and human iPSC models, combined with inter-individual variability, underscores the limitations of current mechanistic models.
Discussion
DYRK1A functions as a dosage‑sensitive regulator orchestrating neurogenesis, chromatin remodeling, synaptic transmission, and glial maturation. Evidence from rodent and human iPSC models underscores mechanistic divergence and inter‑individual variability, complicating translational pathways. Therapeutic strategies, such as small‑molecule inhibitors, CRISPR‑Cas9, and antisense oligonucleotides, show promise but require precise titration to restore equilibrium. Personalized iPSC models, biomarker development, and longitudinal monitoring remain essential for advancing precision medicine approaches targeting dosage‑sensitive genes like DYRK1A.
Conclusion
Therapeutic strategies, such as small-molecule inhibitors (EGCG, harmine), CRISPR-Cas9, and antisense oligonucleotides, demonstrate preclinical efficacy but require precise dosage titration to restore physiological equilibrium without disrupting neurogenic processes. Clinical translation necessitates personalized iPSC models, biomarkers, and longitudinal monitoring. DYRK1A exemplifies precision medicine for dosage-sensitive genes where therapeutic success depends on restoring physiological balance.
This study provides substantial evidence for the vital role of trip12 in the early stages of development, as homozygous individuals exhibited early mortality by Day 23 post-fertilization, while a substantial mortality rate was observed by Day 35 in ‘heterozygous’ mutants.
Maider Roibás-Santos, P. Suarez‐Bregua, J. Rotllant et al.· Brain Communications· 0 citations
Neurodevelopmental disorders are frequently caused by mutations in pleiotropic kinases, yet downstream effectors driving neuronal pathology remain undefined. Here, we identify the G3BP1-dependent stress granule pathway as the dominant effector of casein kinase 2 (CK2α) in developing neurons, implying that its dysregulation underlies the neurodevelopmental deficits of Okur-Chung neurodevelopmental syndrome (OCNDS). OCNDS-associated CK2α mutations reduce phosphorylation of G3BP1 at serine 149, promoting aberrant phase separation and persistent granules that sequester neuronal mRNAs and suppress local protein synthesis across axonal and dendritic compartments. These phenotypes produce allele-specific deficits in neuronal morphogenesis, synaptic abundance, and network excitability, which are conserved in a knock-in mouse model and in patient-derived iPSC neurons. G3bp1 knockdown rescues translational and morphological phenotypes across all OCNDS alleles, demonstrating that restoring granule homeostasis reverses neuronal pathology. Together, these findings establish OCNDS as a disorder of compartment-specific translational dysregulation driven by impaired CK2α–G3BP1 control of RNA granule homeostasis. Summary OCNDS mutations disrupt CK2α–G3BP1 signaling, causing persistent granules and defective neuronal translation and development.
S100A6 (calcyclin) is a multifunctional Ca2+/Zn2+-binding protein of the S100 family, widely expressed in neurons and glia with a developmentally regulated and cell-type-specific pattern. This review synthesizes current knowledge on its roles in the nervous system. We detail its complex interactome, which includes cytoskeletal regulators, molecular chaperones, nuclear transport proteins, and cell surface receptors, positioning S100A6 as a central signaling hub. Furthermore, we examine its dynamic and context-dependent involvement in major neurological disorders. In Alzheimer’s disease and amyotrophic lateral sclerosis, it functions as a glial-derived factor linking protein aggregation, metal dyshomeostasis, and neuroinflammation. In neuro-oncology, S100A6 exhibits dual roles, acting as a promoter of malignancy and immunosuppression in glioblastoma, an epigenetically silenced marker in medulloblastoma, and a diagnostic aid for peripheral nerve sheath tumors. Its expression is also altered in epilepsy, traumatic brain injury, and autoimmune encephalitis. Understanding the nuanced functions of S100A6 offers significant potential for developing novel diagnostic biomarkers and targeted therapeutic strategies for a range of challenging neurological conditions.
Jing Zhang, Peng Tang, Linshu Huang et al.· Frontiers in Pharmacology· 0 citations
Neurodegenerative diseases (NDDs) are a major public health concern characterized by the progressive loss of neurons, ultimately leading to neuronal death and causing a sustained decline in brain function or physical motor abilities. Major examples include Alzheimer’s disease (AD) and Parkinson’s disease (PD). Currently, NDDs lack effective curative methods, and their pathological process primarily involves misfolded protein aggregation, oxidative stress, and neuroinflammation. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, as a central hub for cytokine signaling, has recently been found to play a key role in neuroinflammation and immune regulation in NDDs. This review systematically elucidates the core mechanisms of the JAK/STAT pathway in NDDs, including the regulation of microglial and astrocytic reactivity, the impact on blood–brain barrier integrity, and involvement in energy metabolism abnormalities. On this basis, we have reviewed and evaluated various therapeutic strategies targeting this pathway, focusing on small-molecule JAK inhibitors such as baricitinib and tofacitinib, and have analyzed their mechanisms of action, preclinical efficacy, and potential side effects. In addition, this article provides a forward-looking perspective on the future research directions of the JAK/STAT pathway from the perspective of anti-neuroinflammation to promote neuroregeneration therapy, aiming to offer theoretical references and new ideas for the clinical translational research of this pathway.
Hai-Xia Yang, Bowei Su, Ya-Nan Bao et al.· Frontiers in Aging Neuroscie...· 0 citations
ABSTRACT Neurodegenerative diseases (NDs) are marked by selective neuronal vulnerability and progressive failure of neural circuits. Increasing evidence indicates that neuronal loss is not driven by a single terminal event, but emerges from interacting regulated cell death (RCD) programs. These programs are closely coupled to mitochondrial injury, proteostatic collapse, lysosomal stress, metabolic imbalance, glial state transitions, and chronic neuroinflammation. Yet, how distinct death pathways are organized across cell types, disease stages, and disease‐specific microenvironments remains unresolved. This review examines RCD as an integrated pathogenic network in major NDs. Caspase and B‐cell lymphoma 2 (BCL2) family signaling, receptor‐interacting protein kinase 1 (RIPK1), RIPK3, and mixed lineage kinase domain‐like protein activation, NOD‐like receptor family pyrin domain containing 3 and gasdermin signaling, GPX4‐linked lipid peroxidation control, and autophagy lysosomal failure are discussed as convergent stress response modules rather than isolated pathways. Across Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease, these modules shape neuronal fate through disease‐specific interactions with mitochondrial dysfunction, iron dyshomeostasis, inflammasome activation, and microglial metabolic remodeling. We further evaluate emerging therapeutic strategies that target cell death crosstalk, restore autophagy lysosomal competence, or improve delivery to the central nervous system, highlighting the importance of molecular selectivity, cellular context, disease stage, and translational feasibility.
DYRK1A (dual-specificity tyrosine phosphorylation regulated kinase 1A) is known to play critical roles in regulating numerous cellular functions like cell cycle, neuronal development, and immune homeostasis. Altered expression DYRK1A is implicated in Alzheimer's Disease and various features of Down Syndrome (DS). The DYRK1A gene is located on chromosome 21 and due to trisomy of this chromosome in DS, the level of DYRK1A is elevated in the gene-dosage dependent manner. Nevertheless, how an increase in DYRK1A protein level would affect its activity in DS remains to be determined. The question was examined by performing side by side comparison of protein levels and the activity of DYRK1A extracted from control and DS samples. We show that DYRK1A activity elevation in DS is in parallel to that of DYRK1A protein level regardless of the status of kinase phosphorylation. This suggests that DYRK1A catalytic activity in DS is mainly regulated by protein level.
W. Dowjat, Y. Hwang· Biochemistry and Biophysics...· 0 citations